Table 4.
Cost-effectiveness analysis outcomes for outpatient and inpatient settings.
| Standard care (without any antiviral medication) | Molnupiravir | Nirmatrelvir-ritonavir | |
|---|---|---|---|
| Outpatient setting | |||
| Cost per person (USD) | 367.86 | 1724.56 | 1285.02 |
| Outpatient (designated clinic visit) b | 168.28 | 178.89 | 175.86 |
| Subsequent emergency room visit b | 50.14 | 37.61 | 18.80 |
| Antiviral medications | 0.00 | 1391.11 | 1044.88 |
| Subsequent inpatient healthcare costs b | 149.44 | 116.95 | 45.48 |
| Effectiveness: Probability of surviving during observation period | 99.723% | 99.998% | 100.000% |
| Incremental cost (USD) | - | 1356.70 | 917.16 |
| Incremental effectiveness | - | 0.275% | 0.277% |
| ICERa (USD per death averted) | - | 493,345.09 | 331,105.27 |
| Inpatient setting | |||
| Cost per person (USD) | 8306.35 | 8755.92 | 7040.77 |
| Inpatient healthcare costs b | 8290.68 | 8,440.12 | 6,828.77 |
| Antiviral medications | 0.00 | 306.40 | 205.94 |
| Subsequent emergency room visit b | 15.67 | 9.40 | 6.06 |
| Effectiveness: Probability of surviving during observation period | 74.00% | 91.10% | 97.00% |
| Incremental cost (USD) | - | 449.57 | −1265.58 |
| Incremental effectiveness | - | 17.10% | 23.00% |
| ICERa (USD per death averted) | - | 2629.08 | −5502.53 |
a
ICER: Incremental Cost-Effectiveness Ratio.
b
The cost includes costs occurred for doctor consultation, medical examinations, nursing and prescriptions.